Tradestie Institutional Equity Comparison Engine

JBIO vs AURA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AURA Overall Edge

AURA Captures Institutional Edge (2โ€“1 Pillars ยท 2โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aura Biosciences, Inc. Common Stock (AURA) driven by superior Growth & Margin, Momentum & Technical while JBIO counters with relative strength in Options & Structure. Fundamentally, JBIO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus AURA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, JBIO sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro) against AURA sits in CONSOLIDATION (22nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
JBIO N/M vs AURA N/M Fwd P/E
Growth & Margin Winner AURA
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner AURA
1Y +58.5% vs +30.4% ยท 52W Pos 32% vs 52%
Options & Structure Winner JBIO
BREAKDOWN (6th %ile IV) vs CONSOLIDATION (22nd %ile IV)
JBIO NASDAQ
Jade Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$15.34
-4.96% 1D
Market Cap $1.0B
1M Return +13.88%
1Y Return +58.47%
Forward P/E N/M
Unified AI Score
32.6 / 100 SELL
Tech 20.0 Fund 44.0 Flow 73.0 Mom 50.0
AURA NASDAQ
Aura Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.21
+1.41% 1D
Market Cap $728.6M
1M Return +18.2%
1Y Return +30.38%
Forward P/E N/M
Unified AI Score
28.8 / 100 SELL
Tech 50.0 Fund 39.0 Flow 71.0 Mom 44.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: JBIO +58.47% AURA +30.38% Spread: +28.09 pp (JBIO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
JBIO TTM Op. Margin: 0.0% AURA TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on JBIO vs AURA. Trailing 12-month operating profitability (JBIO 0.0% vs AURA 0.0%) and valuation multiples (JBIO N/M vs AURA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: JBIO (3) vs AURA (2)
Institutional Metric JBIO AURA Criterion Row Winner
Market Capitalization Scale $1.0B $728.6M Larger Scale JBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -89.2% -61.7% Higher ROE AURA
52-Week Range Position Momentum 32% ($10โ€“$28) 52% ($5โ€“$10) Stronger Trend AURA
Beta / 30D Volatility Risk Regime 1.35ฮฒ ยท 60% Vol 0.92ฮฒ ยท 75% Vol Lower Realized Risk JBIO
Unified Institutional Score Composite Signal 32.6 / 100 (SELL) 28.8 / 100 (SELL) Higher Composite JBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full JBIO vs AURA Buy Guide
JBIO BREAKDOWN
141d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live JBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AURA CONSOLIDATION
135d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 22nd %ile
IV Regime Compressed (<25th %ile)
Live AURA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither JBIO nor AURA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.